T
Taito Esaki
Researcher at Kyushu University
Publications - 205
Citations - 4861
Taito Esaki is an academic researcher from Kyushu University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 27, co-authored 172 publications receiving 3415 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara,Mustafa Ozguroglu,Yung-Jue Bang,Maria Di Bartolomeo,Mario Mandalà,Min-Hee Ryu,Lorenzo Fornaro,Tomasz Olesinski,Christian Caglevic,Hyun Cheol Chung,Kei Muro,Eray Goekkurt,Wasat Mansoor,Raymond S. McDermott,Einat Shacham-Shmueli,X. Chen,Carlos Alberto Mayo,S. Peter Kang,Atsushi Ohtsu,Charles S. Fuchs,Guillermo Lerzo,Juan Manuel O'Connor,Guillermo Mendez,James Lynam,Niall C. Tebbutt,Mark Wong,Andrew Strickland,Chris Karapetis,David Goldstein,Paul Vasey,Jean-Luc Van Laethem,Eric Van Cutsem,Scott R. Berry,Mark Vincent,Bettina Muller,Felipe Rey,Angela Zambrano,Joaquin Guerra,Merete Krogh,Lene Baeksgaard,Mette Karen Yilmaz,Anneli Elme,Andrus Magi,Paivi Auvinen,Tuomo Alanko,Markus Moehler,Volker Kunzmann,Thomas Seufferlein,Peter C. Thuss-Patience,Thomas Hoehler,Georg Martin Haag,Salah-Eddin Al-Batran,Hugo Castro,Karla Lopez,Mynor Aguilar Vasquez,Mario Sandoval,Ka On Lam,Sinead Cuffe,Cathy Kelly,Ravit Geva,Ayala Hubert,Alex Beny,Baruch Brenner,Aprile Giuseppe,Alfredo Falcone,Evaristo Maiello,Rodolfo Passalacqua,Vincenzo Montesarchio,Hiroki Hara,Keisho Chin,Tomohiro Nishina,Yoshito Komatsu,Nozumo Machida,Shuichi Hironaka,Taroh Satoh,Takao Tamura,Naotaoshi Sugimoto,Haruhiko Cho,Yashushi Omuro,Ken Kato,Masahiro Goto,Ichinosuke Hyodo,Kazuhiro Yoshida,Hideo Baba,Taito Esaki,Junji Furuse,Wan Zamaniah Wan Mohammed,Carlos Hernandez Hernandez,Juan Casas Garcia,Adriana Dominguez Andrade,Katriona Clarke,Geir Hjortland,Nils Glenjen,Tomasz Kubiatowski,Jassem Jacek,Marek Z. Wojtukiewicz,Sergey Alexandrovich Lazarev,Yuri Lancukhay,Sergey Afanasayev,Vladimir Moiseyenko,Vladimir Kostorov,Svetlana Protsenko,Vadim Shirinkin,Dina Sakaeva,Natalia Fadeeva,Wei Peng Yong,Chau Hsien Matthew Ng,Barbara Robertson,Bernardo Rapaport,Graham Cohen,Lydia Dreosti,Paul Ruff,Conrad Jacobs,Gregory Landers,Waldemar Szpak,Sang-Young Roh,Jeeyun Lee,Yeul Hong Kim,Hyun Cheol Chung,Maria Alsina Maqueda,Federico Longo Munoz,Andres Cervantes Aguilar,Enrique Aranda Aguilar,Pilar Garcia Alfonso,Fernando Rivera,Jaime Feliu Batle,Roberto Pazo Cid,Kun-Huei Yeh,Jen-Shi Chen,Yee Chao,Chia Jui Yen,Oguz Kara,Suayib Yalcin,Daniel Hochhauser,Ian Chau,Al B. Benson,Veena Shankaran,Walid Shaib,Philip A. Philip,Vivek Sharma,Robert J. Siegel,Weijing Sun,Zev A. Wainberg,Ben George,Andrea J. Bullock,Samuel Myrick,Josephine Faruol,Richard M. Siegel,Timothy V. Larson,Carlos Becerra,Suresh Ratnam,Donald A. Richards,Stephen L. Riche +152 more
TL;DR: Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher and had a better safety profile than pac litaxel.
Journal ArticleDOI
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino,Nobuyuki Mizunuma,Kentaro Yamazaki,Tomohiro Nishina,Yoshito Komatsu,Hideo Baba,Akihito Tsuji,Kensei Yamaguchi,Kei Muro,Naotoshi Sugimoto,Yasushi Tsuji,Toshikazu Moriwaki,Taito Esaki,Chikuma Hamada,Takanori Tanase,Atsushi Ohtsu +15 more
TL;DR: In this article, the authors investigated the efficacy and safety of TAS-102 (35 mg/m 2 given orally twice a day in a 28-day cycle [2-week cycle of 5 days of treatment followed by a 2-day rest period, and then a 14-day period] or placebo; all patients received best supportive care.
Journal ArticleDOI
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer.
Ken Kato,Keisho Chin,Takaki Yoshikawa,Kensei Yamaguchi,Yasushi Tsuji,Taito Esaki,Kenji Sakai,Masami Kimura,Tetsuya Hamaguchi,Yasuhiro Shimada,Yasuhiro Matsumura,Ryuji Ikeda +11 more
TL;DR: This study proves the concept for the modest activity and tolerability of a new drug delivery system formulation for PTX in patients with advanced gastric cancer after failure of first-line chemotherapy.
Journal ArticleDOI
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Salvatore Siena,Maria Di Bartolomeo,Kanwal Pratap Singh Raghav,Toshiki Masuishi,Fotios Loupakis,Hisato Kawakami,Kensei Yamaguchi,Tomohiro Nishina,Marwan Fakih,Elena Elez,Javier Rodríguez,Fortunato Ciardiello,Yoshito Komatsu,Taito Esaki,Ki Y Chung,Zev A. Wainberg,Andrea Sartore-Bianchi,Kapil Saxena,Eriko Yamamoto,Emarjola Bako,Yasuyuki Okuda,Javad Shahidi,Axel Grothey,Takayuki Yoshino,Destiny-Crc investigators +24 more
TL;DR: The DESTINY-CRC01 trial as discussed by the authors showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials.
Journal ArticleDOI
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Charles S. Fuchs,Kohei Shitara,Maria Di Bartolomeo,Sara Lonardi,Salah-Eddin Al-Batran,Eric Van Cutsem,David H. Ilson,Maria Alsina,Ian Chau,Jill Lacy,Michel Ducreux,Michel Ducreux,Guillermo Mendez,Alejandro Molina Alavez,Daisuke Takahari,Wasat Mansoor,Peter C. Enzinger,Vera Gorbounova,Zev A. Wainberg,Susanna Hegewisch-Becker,David Ferry,Ji Lin,Roberto Carlesi,Mayukh Das,Manish A. Shah,Manish A. Shah,Alexander Luft,Nina A. Karaseva,Rubén Dario Kowalyszyn,Carlos Alberto Hernandez,Tibor Csoszi,Ferdinando De Vita,Per Pfeiffer,Naotoshi Sugimoto,Judit Kocsis,Andràs Csilla,György Bodoky,Georgina Garnica Jaliffe,Svetlana Protsenko,A Madi,Elzbieta Wojcik,Baruch Brenner,Gunnar Folprecht,Tomasz Sarosiek,Katriina Peltola,Peter Bono,Hubert Ayala,Giuseppe Aprile,Cardellino Giovanni Gerardo,Fidel David Huitzil Melendez,Alfredo Falcone,Francesco Di Costanzo,Moustapha Tehfe,Laurent Mineur,Pilar Garcia Alfonso,Radka Obermannova,Hélène Senellart,Russell D. Petty,Leslie Samuel,Peter Istvan Acs,Maen A. Hussein,Marina N. Nechaeva,F.L.G. Erdkamp,Elizabeth Won,Johanna C. Bendell,Javier Gallego Plazas,Sylvie Lorenzen,Bohuslav Melichar,Miguel Angel Escudero,Denis Pezet,Jean-Marc Phelip,Diego Lucas Kaen,James A. Jr Reeves,Federico Longo Munoz,Srinivasan Madhusudan,Carlo Barone,Luis Fein,Angel Gomez Villanueva,Mohamed Hebbar,Jana Prausová,Laura Visa Turmo,Joana Vidal Barrull,Mette Karen Yilmaz,Alex Beny,H.M.W. Van Laarhoven,Brian Anthony DiCarlo,Taito Esaki,Kazumasa Fujitani,Karen Geboes,Ravit Geva,Shigenori Kadowaki,Stephen Leong,Nozomu Machida,Moses Sundar Raj,Francisco Javier Ramirez Godinez,Agnes Ruzsa,Hugo Ford,William E. Lawler,Nicolas Robert Maisey,Jiri Petera,Einat Shacham-Shmueli,Isabelle Sinapi,Kensei Yamaguchi,Hiroki Hara,J.T. Beck,Maria Błasińska-Morawiec,Ricardo Villalobos Valencia,Thierry Alcindor,Madhuri Bajaj,Scott M. Berry,Christina Maria Gomez,Daniel Dammrich,Ravindranath Patel,Julien Taieb,A.J. Ten Tije,Ronald L. Burkes,Fernando Cabanillas,Irfan Firdaus,Cynthia Coo Chua,Shuichi Hironaka,Ralf-Dieter Hofheinz,Howard J. Lim,Marianne Nordsmark,Bela Piko,Udit Verma,Jonathan Wadsley,Seigo Yukisawa,Francisco Gutiérrez Delgado,Crystal S. Denlinger,Raija Kallio,Joanna Pikiel,Joanna Wojcik-Tomaszewska,Christine Brezden-Masley,Raymond Jang,Jana Pribylova,Daisuke Sakai,Maria Alejandra Bartoli,Annemieke Cats,M.I. Grootscholten,Robert Andrew Dichmann,Hugo Hool,Walid Shaib,Akihito Tsuji,Marc Van den Eynde,Hector Velez-Cortez,Timothy R. Asmis +145 more
TL;DR: The addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.